Landmark A4 Alzheimer's prevention trial now enrolling
Healthy older adults age 65 to 85 with normal memory but who may be at risk of Alzheimer’s are invited to participate in a major clinical trial to prevent or delay the disease.
The trial—Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease, or A4—is testing an experimental drug, solanezumab, to find out if it can help slow memory loss associated with Alzheimer’s. Researchers want to know if starting treatment early in the disease process, before overt symptoms appear, can keep Alzheimer’s at bay.
Investigators are recruiting 1,000 cognitively normal volunteers at 56 sites in the United States, as well 4 in Canada and 1 in Australia. See a list of study sites with contact information.
The A4 Study, led by the Alzheimer’s Disease Cooperative Study, is supported by a public-private partnership funded by the National Institutes of Health, Eli Lilly and Company, and several philanthropic organizations.
Interested in participating? Find out more about the A4 trial.